Clinical Trials List
Protocol NumberV181-003
Completed
2022-03-01 - 2024-10-29
Phase II
Recruiting1
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Po-Liang Lu Division of Infectious Disease
- 張雅婷 Division of Infectious Disease
- Chung-Hao Huang Division of Infectious Disease
- 蔡毓德 Division of Infectious Disease
- Shang-Yi Lin Division of Infectious Disease
- Chun-Yuan Lee Division of Infectious Disease
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
40-50 participants
-
Global
1265 participants
